Immunocore’s ImmTAC platform has the potential to generate development candidates across a range of therapeutic areas in cancer, infectious disease and autoimmune disease. Immunocore advanced its first product candidate, IMCgp100, for the treatment of metastatic melanoma, into human clinical trials in 2010 and has a number of further candidates in the pipeline for the treatment of different cancers, HIV and diabetes.

Immunocore is interested in entering into partnerships with companies which have therapeutic expertise in relevant disease areas and a commitment to development and commercialisation of biologics. Read more »

As well as finding partners for its current programmes, Immunocore is interested in establishing R&D collaborations to generate new ImmTAC reagents against partner-nominated targets for both therapeutic and diagnostic use. Read more »

Immunocore is actively seeking antigens that are validated disease targets and a source of T cell clones.

For further information, please contact Immunocore’s Business Development group at info@immunocore.com.